Selected article for: "amphob treatment and human cov"

Author: Xuesen Zhao; Shuangli Zheng; Danying Chen; Mei Zheng; Xinglin Li; Guoli Li; Hanxin Lin; Jinhong Chang; Hui Zeng; Ju-Tao Guo
Title: LY6E Restricts the Entry of Human Coronaviruses, including the currently pandemic SARS-CoV-2
  • Document date: 2020_4_5
  • ID: dxuabscn_8
    Snippet: . CC-BY-NC-ND 4.0 International license author/funder. It is made available under a The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.04.02.021469 doi: bioRxiv preprint Finally, the findings that LY6E inhibits human CoV entry cannot be evaded by ectopic 284 expression of membrane-associated serine protease TMPRSS2 and compromised by AmphoB 285 treatment strongly indicate that LY6E modulates.....
    Document: . CC-BY-NC-ND 4.0 International license author/funder. It is made available under a The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.04.02.021469 doi: bioRxiv preprint Finally, the findings that LY6E inhibits human CoV entry cannot be evaded by ectopic 284 expression of membrane-associated serine protease TMPRSS2 and compromised by AmphoB 285 treatment strongly indicate that LY6E modulates virus entry via a distinct mechanism from that 286 IFITM proteins do (Figs. 7 and 8) . Specifically, inhibition of TMPESS2-enhanced CoV entry 287 implies that LY6E most likely blocks virus entry at plasma membrane or in early endosomes. 288

    Search related documents:
    Co phrase search for related documents